Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure Results From the COSMIC-HF Study

被引:9
作者
Felker, G. Michael [1 ,2 ]
Solomon, Scott D. [3 ]
McMurray, John J. V. [4 ]
Cleland, John G. F. [5 ,6 ]
Abbasi, Siddique A. [7 ]
Malik, Fady I. [8 ]
Zhang, Hanze [7 ]
Globe, Gary [7 ]
Teerlink, John R. [9 ,10 ]
机构
[1] Duke Clin Res Inst, 200 Morris St, Durham, NC 27705 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[4] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Glasgow Royal Infirm, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[6] Imperial Coll, Natl Heart & Lung Inst, London, England
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Cytokinetics Inc, San Francisco, CA USA
[9] San Francisco VA Med Ctr, Sect Cardiol, San Francisco, CA USA
[10] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA
关键词
heart failure; longitudinal studies; quality of life; stroke volume; systole; CARDIAC MYOSIN ACTIVATOR; PHASE-2;
D O I
10.1161/CIRCHEARTFAILURE.120.007814
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Chronic heart failure with reduced ejection fraction impairs health-related quality of life (HRQL). Omecamtiv mecarbil (OM)-a novel activator of cardiac myosin-improves left ventricular systolic function and remodeling and reduces natriuretic peptides. We sought to evaluate the effect of OM on symptoms and HRQL in patients with chronic heart failure with reduced ejection fraction and elevated natriuretic peptides enrolled in the COSMIC-HF trial (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). METHODS: Patients (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guided dose titration (OM-PK) for 20 weeks. The Kansas City Cardiomyopathy Questionnaire was administered to assess HRQL at baseline, 16 weeks, and 20 weeks. The primary scores of interest were the Total Symptom Score, Physical Limitation Scale, and Clinical Summary Score. RESULTS: Mean change in score from baseline to 20 weeks for the Total Symptom Score was 5.0 (95% CI, 1.8-8.1) for placebo, 6.6 (95% CI, 3.4-9.8) for OM 25 mg (P=0.32 versus placebo), and 9.9 (95% CI, 6.7-13.0) for OM-PK (P=0.03 versus placebo); for the Physical Limitation Scale, it was 3.1 for placebo (95% CI, -0.3 to 6.6), 6.0 (95% CI, 3.1-8.9) for OM 25 mg (P=0.12), and 4.3 (95% CI, 0.7-7.9) for OM-PK (P=0.42); for the Clinical Summary Score, it was 4.1 (95% CI, 1.4-6.9) for placebo, 6.3 (95% CI, 3.6-9.0) for OM 25 mg (P=0.19), and 7.0 (95% CI, 4.1-10.0) for OM-PK (P=0.14). Differences between OM and placebo were greater in patients who were more symptomatic at baseline. CONCLUSIONS: HRQL as measured by the Total Symptom Score improved in patients with heart failure with reduced ejection fraction assigned to the OM-PK group relative to placebo. Ongoing trials are prospectively testing whether OM improves symptoms and HRQL in heart failure with reduced ejection fraction. REGISTRATION: URL: ; Unique identifier: NCT01786512.
引用
收藏
页数:8
相关论文
共 18 条
  • [1] The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
    Cleland, John G. F.
    Teerlink, John R.
    Senior, Roxy
    Nifontov, Evgeny M.
    Mc Murray, John J. V.
    Lang, Chim C.
    Tsyrlin, Vitaly A.
    Greenberg, Barry H.
    Mayet, Jamil
    Francis, Darrel P.
    Shaburishvili, Tamaz
    Monaghan, Mark
    Saltzberg, Mitchell
    Neyses, Ludwig
    Wasserman, Scott M.
    Lee, Jacqueline H.
    Saikali, Khalil G.
    Clarke, Cyril P.
    Goldman, Jonathan H.
    Wolff, Andrew A.
    Malik, Fady I.
    [J]. LANCET, 2011, 378 (9792) : 676 - 683
  • [2] Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study
    Cleland, Joltn G. F.
    Calvert, Melanie J.
    Verboven, Yves
    Freemantle, Nick
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (03) : 457 - 466
  • [3] The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis
    Dobre, Daniela
    van Jaarsveld, Cornelia H. M.
    deJongste, Mike J. L.
    Haaijer-Ruskamp, Flora M.
    Ranchor, Adelita V.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (02) : 152 - 159
  • [4] FDA Gov, 2020, QUAL KANS CIT CARD Q
  • [5] Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure HF-ACTION Randomized Controlled Trial
    Flynn, Kathryn E.
    Pina, Ileana L.
    Whellan, David J.
    Lin, Li
    Blumenthal, James A.
    Ellis, Stephen J.
    Fine, Lawrence J.
    Howlett, Jonathan G.
    Keteyian, Steven J.
    Kitzman, Dalane W.
    Kraus, William E.
    Miller, Nancy Houston
    Schulman, Kevin A.
    Spertus, John A.
    O'Connor, Christopher M.
    Weinfurt, Kevin P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (14): : 1451 - 1459
  • [6] Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure
    Green, CP
    Porter, CB
    Bresnahan, DR
    Spertus, JA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (05) : 1245 - 1255
  • [7] Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
    Kosiborod, Mikhail N.
    Jhund, Pardeep S.
    Docherty, Kieran F.
    Diez, Mirta
    Petrie, Mark C.
    Verma, Subodh
    Nicolau, Jose C.
    Merkely, Bela
    Kitakaze, Masafumi
    DeMets, David L.
    Inzucchi, Silvio E.
    Kober, Lars
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Solomon, Scott D.
    Bengtsson, Olof
    Lindholm, Daniel
    Niklasson, Anna
    Sjoestrand, Mikaela
    Langkilde, Anna Maria
    McMurray, John J. V.
    [J]. CIRCULATION, 2020, 141 (02) : 90 - 99
  • [8] Health-Related Quality of Life Outcomes in PARADIGM-HF
    Lewis, Eldrin F.
    Claggett, Brian L.
    McMurray, John J. V.
    Packer, Milton
    Lefkowitz, Martin P.
    Rouleau, Jean L.
    Liu, Jiankang
    Shi, Victor C.
    Zile, Michael R.
    Desai, Akshay S.
    Solomon, Scott D.
    Swedberg, Karl
    [J]. CIRCULATION-HEART FAILURE, 2017, 10 (08)
  • [9] Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
    Malik, Fady I.
    Hartman, James J.
    Elias, Kathleen A.
    Morgan, Bradley P.
    Rodriguez, Hector
    Brejc, Katjusa
    Anderson, Robert L.
    Sueoka, Sandra H.
    Lee, Kenneth H.
    Finer, Jeffrey T.
    Sakowicz, Roman
    Baliga, Ramesh
    Cox, David R.
    Garard, Marc
    Godinez, Guillermo
    Kawas, Raja
    Kraynack, Erica
    Lenzi, David
    Lu, Pu Ping
    Muci, Alexander
    Niu, Congrong
    Qian, Xiangping
    Pierce, Daniel W.
    Pokrovskii, Maria
    Suehiro, Ion
    Sylvester, Sheila
    Tochimoto, Todd
    Valdez, Corey
    Wang, Wenyue
    Katori, Tatsuo
    Kass, David A.
    Shen, You-Tang
    Vatner, Stephen F.
    Morgans, David J.
    [J]. SCIENCE, 2011, 331 (6023) : 1439 - 1443
  • [10] Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
    McMurray, John J. V.
    Packer, Milton
    Desai, Akshay S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 993 - 1004